Rodriguez Eric G, Dodge Hiroko H, Birzescu Maria A, Stoehr Gary P, Ganguli Mary
Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
J Am Geriatr Soc. 2002 Nov;50(11):1852-6. doi: 10.1046/j.1532-5415.2002.50515.x.
To compare the use of lipid-lowering drugs in community-dwelling older adults with and without dementia.
Comparison of lipid-lowering drug use by demented cases and nondemented controls based on secondary analysis of data from a longitudinal epidemiologic study.
Longitudinal study of a largely rural, low- socioeconomic-status, community-based cohort of older persons residing in the mid-Monongahela Valley of South-west Pennsylvania (the Monongahela Valley Independent Elders Survey).
Eight hundred forty-five individuals of mean +/- standard deviation (SD) age of 80.5 +/- 4.6, participating in the fifth biennial wave of data collection.
Demographics; medical history; medication regimen (including examination of prescription bottle labels); self-report of most recent visit to primary care physician (PCP); and standardized clinical assessment to determine presence of dementia, including Clinical Dementia Rating (CDR).
One hundred seventy participants (20.1% of total subject cohort) had dementia, with a CDR of 0.5 or greater. Mean ages of demented and nondemented individuals were 83.5 +/- 5.1 and 79.8 +/- 4.2, respectively. Similar proportions, 87.7% and 89.5%, of these groups reported PCP visits in the previous year. Of the total sample, 9.4% (3.5% of the demented and 10.8% of the nondemented) were taking lipid-lowering drugs. After adjustment for age, sex, education, visit with PCP within the past year, and potential confounding clinical and lifestyle variables (self-reported heart disease, stroke or transient ischemic attacks, hypertension, smoking, and alcohol consumption), dementia was associated with a lower likelihood of taking a lipid-lowering drug (odds ratio = 0.39, 95% confidence interval = 0.16-0.95). In post hoc subgroup analyses, similar results were found when restricting lipid-lowering drugs to statins alone but were not statistically significant. Drug use was not associated with severity of dementia (CDR = 0.5 vs CDR >or= 1).
Demented individuals were less likely than their nondemented counterparts to be taking lipid-lowering drugs. This finding could reflect different prescribing patterns by physicians for demented and nondemented patients or a possible protective effect of these drugs against dementia.
比较在有痴呆症和无痴呆症的社区居住老年人中降脂药物的使用情况。
基于一项纵向流行病学研究数据的二次分析,对痴呆病例和非痴呆对照的降脂药物使用情况进行比较。
对宾夕法尼亚西南部莫农加希拉河谷(莫农加希拉河谷独立老年人调查)一个以农村为主、社会经济地位较低的社区老年人队列进行纵向研究。
845名个体,平均年龄±标准差(SD)为80.5±4.6岁,参与了第五次两年一次的数据收集。
人口统计学;病史;用药方案(包括检查药瓶标签);最近一次就诊于初级保健医生(PCP)的自我报告;以及用于确定痴呆症存在的标准化临床评估,包括临床痴呆评定量表(CDR)。
170名参与者(占总研究队列的20.1%)患有痴呆症,CDR为0.5或更高。痴呆症患者和非痴呆症患者的平均年龄分别为83.5±5.1岁和79.8±4.2岁。这些组中分别有87.7%和89.5%的人报告在前一年就诊于PCP。在整个样本中,9.4%(痴呆症患者中为3.5%,非痴呆症患者中为10.8%)正在服用降脂药物。在对年龄、性别、教育程度、过去一年就诊于PCP以及潜在的混杂临床和生活方式变量(自我报告的心脏病、中风或短暂性脑缺血发作、高血压、吸烟和饮酒)进行调整后,痴呆症与服用降脂药物的可能性较低相关(比值比=0.39,95%置信区间=0.16 - 0.95)。在事后亚组分析中,当仅将降脂药物限制为他汀类药物时发现了类似结果,但无统计学意义。药物使用与痴呆症严重程度(CDR = 0.5与CDR≥1)无关。
与非痴呆症患者相比,痴呆症患者服用降脂药物的可能性较小。这一发现可能反映了医生对痴呆症患者和非痴呆症患者不同的开药模式,或者这些药物对痴呆症可能具有保护作用。